TGFB1 and cervical cancer: Previous studies have revealed that cervical cancer cases with low expression of TGFBR2 have a poor prognosis and have confirmed that TGFBR2 can inhibit the cell cycle process at the G1/S stage through the TGFB/Smad pathway, while low expression of TGFBR2 can alleviate the inhibitory effect of this pathway, thereby speeding up cervical cancer cell progression from the G1 phase to the S phase and resulting in cell proliferation [14].